Related Experiment Video
Updated: May 6, 2026
A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
Published on: October 14, 2016
Chronic Myelogenous Leukemia, Version 1.2014
Susan O'Brien1, Jerald P Radich, Camille N Abboud
1From 1The University of Texas MD Anderson Cancer Center; 2Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 4Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; 5Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 6Memorial Sloan-Kettering Cancer Center; 7Dana-Farber/Brigham & Women's Cancer Center; 8Huntsman Cancer Institute at the University of Utah; 9The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 10Massachusetts General Hospital Cancer Center; 11Stanford Cancer Institute; 12Vanderbilt-Ingram Cancer Center; 13Fox Chase Cancer Center; 14Duke Cancer Institute; 15St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 16Moffitt Cancer Center; 17University of Alabama at Birmingham Comprehensive Cancer Center; 18UCSF Helen Diller Family Comprehensive Cancer Center; 19The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 20City of Hope Comprehensive Cancer Center; 21Roswell Park Cancer Institute; and 22National Comprehensive Cancer Network.
Abstract:
The 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia recommend quantitative reverse-transcription polymerase chain reaction (QPCR) standardized to International Scale (IS) as the preferred method for monitoring molecular response to tyrosine kinase inhibitor (TKI) therapy. A BCR-ABL1 transcript level of 10% or less (IS) is now included as the response milestone at 3 and 6 months. Change of therapy to an alternate TKI is recommended for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with imatinib. Continuing the same dose of TKI or switching to an alternate TKI are options for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with dasatinib or nilotinib. The guidelines recommend 6-month evaluation with QPCR (IS) for patients with BCR-ABL1 transcript levels greater than 10% at 3 months. Monitoring with QPCR (IS) every 3 months is recommended for all patients, including those who meet response milestones at 3, 6, 12, and 18 months (BCR-ABL1 transcript level ≤10% [IS] at 3 and 6 months, complete cytogenetic response at 12 and 18 months).
More Related Videos
06:28Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
Published on: November 10, 2023
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
